Cantuzumab ravtansine, also called IMGN242 or huC242-DM4, 868747-45-9, is an antibody-drug conjugate (ADC) developed to treat cancers. It combines cantuzumab, a humanized monoclonal antibody that targets the CanAg antigen, with ravtansine (DM4), a highly potent cytotoxic agent. This approach delivers the drug directly to CanAg-expressing tumor cells, enhancing its effectiveness while reducing side effects.
Key Features
- Targeted Therapy: Specifically binds to CanAg, a glycoform of MUC1, often overexpressed in cancers like pancreatic, biliary, and colorectal cancers.
- Mechanism of Action: The ADC binds to CanAg on the tumor cell surface, is internalized, and releases DM4. DM4 disrupts microtubules, stopping cell division and triggering apoptosis.
- Precision Medicine: Minimizes harm to healthy cells by focusing on cancer-specific antigens.
Applications
- Pancreatic Cancer: Investigated for its ability to target CanAg-expressing pancreatic tumors.
- Biliary Cancer: Explored as a treatment for cancers in the bile ducts with high CanAg expression.
- Colorectal Cancer: Studied for potential efficacy in targeting CanAg-positive colorectal tumors.
- Targeted Therapy Research: Used as a model to refine ADC technologies and improve cancer treatment.
- Preclinical Studies: Supports research into CanAg-targeted cancer therapies.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.